I-Mab Biopharma   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2016)

Organization Overview

First Clinical Trial
2019
NCT03860038
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

I-Mab Biopharma | I-Mab Biopharma Co. Ltd. | I-Mab Biopharma HongKong Limited | I-Mab Biopharma US Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 1)

Arthritis, Rheumatoid (Phase 1)

Coronavirus Infections (Phase 2)

Glioblastoma (Phase 2)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma (Phase 1)

Multiple Myeloma (Phase 3)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 17